https://www.thepharmaletter.com/article/effective-vaccines-on-the-way-for-massive-public-health-threat
0
0
Initial safety and immunogenicity results from a Phase III trial of Bavarian Nordic's (OMX: BAVA) chikungunya virus vaccine candidate have been announced. The candidate is known as PXVX0317. The company said that the study has already met its primary efficacy endpoints, with a strong induction of chikungunya virus neutralizing antibodies having been observed in 87% of those receiving the ... - The Pharma Letter
6/21/23 at 3:47am
Organization
The Pharma Letter
Authors
Details
84 words
Summarize
Infectious Diseases Health Bavarian Nordic chikungunya virus vaccine candidate BAVA efficacy endpoints The Pharma Letter
Initial safety and immunogenicity results from a Phase III trial of Bavarian Nordic’s chikungunya virus vaccine candidate have been announced.
Create an account or login to join the discussion